SERPINE1 and breast cancer: We carried out experiments to investigate whether the COX-2 inhibitor celecoxib at a dose of either 200 mg bid or 400 mg bid could significantly affect endogenous uPA, PAI-1 or PGE2 production in women at increased risk for breast cancer.